JAMA Oncology

Medications

Tislelizumab plus chemo slows advanced squamous NSCLC

(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...

Oncology & Cancer

Study finds racial disparities in breast cancer prognosis testing

Black women have higher recurrence and mortality rates than non-Hispanic white women for certain types of breast cancer, according to a University of Illinois Chicago researcher's study published recently in JAMA Oncology.

page 19 from 40